SAN DIEGO, Calif. — September 3, 2025 — Leads & Copy — Adagene Inc. (Nasdaq: ADAG) has appointed Dr. Axel Hoos as Executive Advisor. Dr. Hoos will provide guidance as Adagene advances its pipeline of antibody-based therapies, including ADG126, which is currently in phase 1b/2 clinical studies, and expands its SAFEbody™ pipeline.
According to Dr. Hoos, Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. He notes that the design of Adagene’s antibodies may allow a broader utility of CTLA-4 targeting in cancer immunotherapy, potentially shifting the benefit/risk ratio of CTLA-4 targeting and allowing treatment of new populations such as cold tumors like MSS CRC.
Peter Luo, CEO of Adagene, stated that Dr. Hoos is an icon in immuno-oncology. From 2021 to 2024 Dr. Hoos served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly in 2025. Previously, Dr. Hoos was the SVP and Head of the Oncology Therapeutic Area at GSK. Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS).
Dr. Hoos received his M.D. in Medicine from Heidelberg University, and his Ph.D. in Molecular Oncology from the German Cancer Research Center (DKFZ). He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center and is an alumnus of the Program for Leadership Development at Harvard Business School.
Investor Contacts:Raymond Tam, raymond_tam@adagene.com; Corey Davis, Ph.D., LifeSci Advisors, cdavis@lifesciadvisors.com
Source: Adagene Inc.
